While sorafenib is not considered effective for the treatment of most melanomas with BRAF V600E mutations, it may be effective in the treatment of a minority of melanomas with G469E and D594G mutations which express constitutive ERK1/2 but low levels of MEK. Here, MAP2K7 is linked to melanoma.